Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2025-12-25 @ 12:10 AM
NCT ID:
NCT00415558
Eligibility Criteria:
Inclusion Criteria:
* Patient is greater than or = 18 years of age
* Patient has documented symptomatic paroxysmal atrial fibrillation (PAF) refractory to at least 1 antiarrhythmic (Class IA, IC, III) drug.
* Patient has episodes of symptomatic AF including, but not limited to, palpitations, lightheadedness, fatigue, dyspnea, and/or chest pain.
* A minimum of a 6-month history of symptomatic paroxysmal AF (documented by patient report in the medical record).
* A minimum of 2 discrete symptomatic paroxysmal AF episodes in the month prior to study entry. Paroxysmal AF rhythm must be documented by objective evidence (12-lead electrocardiogram \[ECG\], Holter monitor, event monitor, or other telemetry rhythm strip) with the presence of sinus rhythm and/or underlying rhythm between episodes.
* Patient has been informed of the nature of the study, agreed to its provisions, and provided written informed consent.
Exclusion Criteria:
* Patient had a cerebral vascular accident or transient ischemic attack within the previous 6 months.
* Patient had a myocardial infarction within the previous 6 weeks.
* Patient has underlying metabolic etiology related to AF (e.g., hyperthyroidism, metabolic disorder).
* Patient has significant underlying structural heart disease (e.g., valvular disease, presence of aneurysm, left ventricular hypertrophy) requiring surgical or procedural intervention.
* Patient with prior catheter ablation procedure for the treatment of AF within the previous 6 months.
* Patient has evidence of, or history of, 50% or more stenosis in any pulmonary vein.
* Patient had a previous thoracic procedure resulting in sternal opening and/or pericardial opening (e.g., surgical ablation, coronary artery bypass graft \[CABG\], or valve repair).
* Patient has a left atrial size \> 6.0 cm measured on echocardiogram.
* Patient has a left ventricular ejection fraction (LVEF) \< 35%.
* Patient requires treatment for CAD (coronary artery disease) or has untreated unstable angina.
* Patient has a presence of esophageal fistula or esophageal stricture, untreated esophagitis, varices, dysphagia, or odynophagia caused by anatomical abnormality or other diseases contraindicating transesophageal echocardiography.
* Patient has severe chronic obstructive pulmonary disease.
* Patient has a known allergy or contraindication to Coumadin (warfarin) therapy, or inability to comply with Coumadin (warfarin) therapy.
* Patient has a known allergy or contraindication to complying with antiarrhythmic (Class IA, IC, III) therapy.
* Patient has an acute illness or active systemic infection or sepsis.
* Patient has a co-morbidity with life expectancy of less than one year or protocol non-compliance that would limit follow-up.
* Patient is geographically remote and/or unable to return for follow-up examinations.
* Patient is pregnant or is planning to become pregnant during the study.
* Patient is enrolled in any concurrent study.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00415558
Study Brief:
Protocol Section:
NCT00415558